losartan and ADPKD
losartan has been researched along with ADPKD in 4 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, effective BP control was obtained with losartan and ramipril and LVH was found to be regressed significantly in the hypertensive patients with ADPKD." | 5.14 | A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease. ( Kaynar, K; Kiriş, A; Koşucu, P; Orem, C; Ozkan, G; Ulusoy, S, 2010) |
| "With treatment of prednisolone, an angiotensin-converting enzyme inhibitor, and an angiotensin II receptor-blocker, his proteinuria markedly decreased and renal function was stabilized." | 2.43 | Nephrotic syndrome and IgA nephropathy in polycystic kidney disease. ( Gejyo, F; Hiura, T; Kawabe, S; Miyamura, S; Nishi, S; Saeki, T; Ueno, M; Yamazaki, H, 2006) |
| "Proteinuria is a sign of established kidney damage and plays a direct pathogenic role in the progression of renal and cardiovascular disease." | 2.43 | Time to abandon microalbuminuria? ( Remuzzi, G; Ruggenenti, P, 2006) |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ulusoy, S | 1 |
| Ozkan, G | 1 |
| Orem, C | 1 |
| Kaynar, K | 1 |
| Koşucu, P | 1 |
| Kiriş, A | 1 |
| Hiura, T | 1 |
| Yamazaki, H | 1 |
| Saeki, T | 1 |
| Kawabe, S | 1 |
| Ueno, M | 1 |
| Nishi, S | 1 |
| Miyamura, S | 1 |
| Gejyo, F | 1 |
| Ruggenenti, P | 1 |
| Remuzzi, G | 1 |
| Goffin, E | 1 |
| Pochet, JM | 1 |
| Lejuste, P | 1 |
| De Plaen, JF | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
HbA1C Levels
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Number of Participants With Hypoglycemia
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight Change During Trial
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
Reviews
2 reviews available for losartan and ADPKD
| Article | Year |
|---|---|
Nephrotic syndrome and IgA nephropathy in polycystic kidney disease.
Topics: Aged; Biopsy; Dipyridamole; Glomerulonephritis, IGA; Humans; Kidney; Losartan; Male; Nephrotic Syndr | 2006 |
Time to abandon microalbuminuria?
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biomarkers; | 2006 |
Trials
1 trial available for losartan and ADPKD
| Article | Year |
|---|---|
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2010 |
Other Studies
1 other study available for losartan and ADPKD
| Article | Year |
|---|---|
Aphtous ulcers of the mouth associated with losartan.
Topics: Antihypertensive Agents; Dysgeusia; Female; Humans; Hypertension; Kidney Failure, Chronic; Lisinopri | 1998 |